Compare Enveric Biosciences Inc (ENVB) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Gitlab Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Gitlab Inc trades at $41.97 (market cap $6.88B). The key difference: Gitlab Inc is far larger — about 1109.7× Enveric Biosciences Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | GTLB | |
|---|---|---|
Market Cap | $6.20M | $6.88B |
Sector | Health | Technology |
52-Week High | $17.40 | $51.04 |
52-Week Low | $1.27 | $19.42 |
Enterprise Value | $1.30M | $5.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
GitLab (GTLB) trades at $38.97, up 9.22% in 24 hours, with a bullish technical signal and recent earnings beats. The stock shows strong revenue growth, reaching $759.25M in 2025, but remains unprofitable with a negative net income margin. Analyst consensus is mixed, with 36.67% buy ratings and a $32.92 price target, while recent news highlights AI-driven product launches and leadership appointments.
Outlook: GitLab's growth trajectory and AI integration offer upside, but high valuation and persistent losses pose risks. Investors should weigh revenue momentum against profitability challenges and competitive pressures in the DevSecOps space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
